85% of AA drugs are in oncology I don't have access to the full article but it seems like the AA designation is very common for cancer drugs.
Executive Summary
US FDA’s Oncology Center of Excellence Director and the National Institutes of Health National Cancer Institute Director defended the agency’s accelerated approval pathway, saying critics are missing the benefits reaped by many cancer patients. Pazdur worries pathway is at risk, unless champions work to counter critics.
FDA Cancer Head Defends Path Used for Biogen Alzheimer Approval
BY JEANNIE BAUMANN
July 29, 2021, 1:39 PM
- Biogen’s Aduhelm spurred criticism of accelerated approval
- 85% of accelerated approval drugs are in oncology
The FDA’s cancer chief pushed back against criticisms over the agency’s expedited approval mechanisms, calling them one-sided arguments that fail to recognize the benefits of making potentially lifesaving treatments available more quickly.
“Do you think accelerated approval is under attack? I do,” Richard Pazdur, director of the Food and Drug Administration’s Oncology Center of Excellence, said Thursday at a Friends of Cancer Research online event.
Pazdur’s remarks follow the FDA’s controversial decision to grant accelerated approval to Biogen’s Alzheimer’s drug. It prompted the resignations of several scientists on the agency’s advisory panel, which said there was incomplete data on the ...
https://news.bloomberglaw.com/health-law-and-business/fda-cancer-head-defends-path-used-for-biogen-alzheimer-approval